Management of bone metastases in refractory prostate cancer – role of denosumab
Channing J Paller,1 Michael A Carducci,1 George K Philips21Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; 2Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USAAbstract: This article reviews the problem of bone disease in prostate cancer and the evolvin...
Main Authors: | Paller CJ, Carducci MA, Philips GK |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-09-01
|
Series: | Clinical Interventions in Aging |
Subjects: | |
Online Access: | https://www.dovepress.com/management-of-bone-metastases-in-refractory-prostate-cancer-ndash-role-peer-reviewed-article-CIA |
Similar Items
-
Treatment of medullary thyroid cancer with bone metastases with denosumab: A review and case illustration
by: Leslie S. Eldeiry, et al.
Published: (2020-09-01) -
Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience
by: Nigora Rasulova, et al.
Published: (2013-01-01) -
Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
by: Miriam Hegemann, et al.
Published: (2019-01-01) -
Current approaches to therapy for complications of bone metastases from breast cancer
by: L. G. Zhukova
Published: (2014-07-01) -
Pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases
by: A. S. Kolbin, et al.
Published: (2018-05-01)